Yes, of course. If you are interested in visiting CinnaGen and

  • You are a researcher or student: please send a recommendation letter from our institution to info@cinnagen.com or send it by fax to 00982142915231
  • You are a potential business partner: please send your request to bd@cinnagen.com or send it by fax to 00982188561575
  • You are a medical doctor or a nurse: please send your request to ask@orchidpharmed.com or send it by fax to 00982188562862


Please send an email to bd@cinnagen.com or call 00982142815


No, we don’t employ university students

All employees shall work on full time basis. Working hours are defined in accordance with work hours approved by Labor Law.

Upon a week after interview, the result would be informed to applicant. If the applicant will not be phoned, it shall be considered as refusal of application

  • Image of all pages of birth certificate.
  • 2 pieces of 3*4 photos.
  • Images of first and second page of spouse’s birth certificate.
  • Images of first pages of birth certificates of children.
  • Image of first page of insurance booklet
  • Images of other family members’ birth certificates (those who are under the support of applicant) as well as their insurance policies (booklet) 
  • Images of applicant’s and his/her family members ID card (those who are under the support of applicant)
  • A photocopy from the military service completion card or military service exemption card for male applicants
  • A photocopy of latest educational degrees
  • A photocopy of employment and insurance records
  • Certificate of clean record and no addiction
  • Technical interview (If needed)
  • Interview with related deputy manager and HR manager
  • Recruitment panel (if needed and in accordance with job)
  • Interview with CEO of the company (If needed)

Yes, you can send your résumé via email or fax.


CinnaFact® injectable solution should be clear and particle-free. Otherwise, do not use it. In addition, do not use the product after the expiration date.

It is advisable that CinnaFact® reach to the room temperature prior to injection. For this purpose, a maximum of half an hour is sufficient.

If injection site reactions such as pain, redness, inflammation, etc. occur, it is better to delay bathing until symptoms are resolved. Otherwise, bathing is permitted half an hour after the injection.

CinnaFact® should be administered subcutaneously at a 90° angle. The best areas for administration of CinnaFact® are:

  • Front of the thighs (at least 7.5 cm below the hip and above the knees).
  • Belly (below the ribs and above the hip bone, at least 5 cm away from the belly button).

Administration of CinnaFact® in therapeutic doses results in suppression of the pituitary-gonadal system. Normal function is usually restored after a few weeks of last dose of CinnaFact®. Diagnostic tests of pituitary-gonadal function conducted during the treatment and within a few weeks after discontinuation of CinnaFact® therapy may therefore be misleading.

Overdose may lead to signs and symptoms such as asthenia, headache, nervousness, hot flushes, dizziness, nausea, abdominal pain, edemas of the lower extremities, mastodynia and local reactions at the injection site such as pain, hemorrhage and induration.

Metabolic inactivation by peptidases occurs in the liver and kidney. The drug is also inactivated by pituitary membrane enzymes.

During treatment with CinnaFact®, the effect of antidiabetic agents may be attenuated. Since androgen deprivation treatment may prolong the QT interval, the concomitant use of CinnaFact® with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes, such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics, etc. should be carefully evaluated.


CinnoRA® is available in Auto Injector device. It can be administered as a subcutaneous injection easily by the patient. The patient should be trained by a pharmacist, doctor or nurse before self-injection.

-Use the medicine as soon as you remember, and then go back to your regular injection schedule.

-Do not use extra medicine to make up the missed dose. Do not take 2 doses at the same time or extra doses.

-If it is close to the time for your next dose, skip the missed dose and go back to your normal time.

Always keep CinnoRA® in a refrigerator (2°C-8°C/36°F-46°F) and keep pre-filled syringes in the outer carton in order to protect from light.

Do not use the drug if the liquid is cloudy or discolored.

Remove the syringe from the refrigerator. Leave at room temperature for 15-30 minutes before using. Do not remove needle cover while allowing it to reach room temperature. Do not warm CinnoRA® in any other way (eg, do not warm in a microwave or under hot water).

Warning signs of a serious allergic reaction may include rash, swollen, tightness in throat or chest, swelling of the mouth, throat or tongue, hives and itching. If you experience any of these symptoms, call your doctor immediately.

Always inform your doctor if you are pregnant or planning to become pregnant, breastfeeding or planning to breastfeed before using any medicine. This drug should only be used during pregnancy if the benefit outweighs the risk to the fetus.

Tell your doctor about all of your health conditions, including if you:

-Have an infection, are being treated for infection, or have symptoms of an infection

-Are scheduled for major surgery

-Have TB or living in an endemic region or have a contact with a patient with TB.

-Have Hepatitis B or have a history of Hepatitis B

-Have or have had cancer

-A nervous system disease such as multiple sclerosis or Guillain-Barre syndrome

- Have or had heart failure

-Have diabetes

 -Are allergic to any CinnoRA® or any ingredients of it.

-Are pregnant, planning to be pregnant, breastfeeding or planning to breastfeed

-Have recently received or are scheduled to receive e vaccine.

-Know the medicines you take. Keep a list of your medicines with you to show your doctor and pharmacist each time you get a new medicine.

Baseline monitoring:

Monitor latent TB screening prior to initiating, HBV screening prior to initiating.

LFT and CBC with differential prior to initiating, Signs or symptoms of active infection, including tuberculosis.


Ongoing monitoring:

Monitor latent TB during therapy (Consider at least a yearly PPD); Periodic CBC with differential; HBV carriers (during and for several months following therapy); LFT*;

*For other two drugs, the decision should be made by physician based on the case.

Signs or symptoms of active infection, including tuberculosis (during, and following therapy);



Periodic history, physical examination and monitoring for improvement of signs, symptoms, or worsening of heart failure, signs and symptoms of hypersensitivity reaction; symptoms of lupus-like syndrome; signs or symptoms of malignancy (including periodic skin examination) or signs or symptoms of demyelinating disorders (eg, multiple sclerosis, Guillain-Barré syndrome) are recommended while on treatment.

The recommended initial dose of CinnoRA® for adult patients with crohn’s disease, ulcerative colitis and hidradenitis suppurativa is 160 mg which can be given as four 40 mg injections on day 1 or split as two 40 mg injections per day over two consecutive days.


  • You should not take CinnoPar® for more than 2 years over your lifetime.
  • You should not take CinnoPar® if you are allergic to any Ingredients of CinnoPar®, because some serious allergic reactions have been reported.  
  • If you have any bone related diseases other than osteoporosis, like bone cancer.
  • If you have problem with self-injection or you have nobody to help you.
  • If you have or have had kidney stones.
  • If have or have had too much calcium in your blood

If you’re taking medication such as digoxin, furosemide or hydrochlortiazide.

  • If you have any medical condition.
  • If you are pregnant or thinking about becoming pregnant, it is not known if teriparatide will harm your unborn baby.
  • Teriparatide effect has not been studied during breastfeeding. Consult your doctor before use CinnoPar®.


  • CinnoPar® can cause some side effects such as decrease in blood pressure when changing your positions.
  • Some people experience dizziness, fast heart beat or feel faint right after first few doses. This usually happens within 4 hours of taking CinnoPar® and goes away within a few hours.

    For the first few doses, take your injections of CinnoPar® in a place where you can sit or lie down right away if you get these symptoms. If these side effects didn’t get away or got worst, stop taking CinnoPar® and consult your doctor.


  • CinnoPar® may increase blood calcium level. If you’re experiencing nausea, vomiting, constipation, fatigue, muscle weakness, call your doctor. these maybe signs of high blood calcium level.
  • Teriparatide common side effects are nausea, joint aches, leg crump, Injection site reaction including site pain, swelling and bruising.

    These are not all the possible side effects of CinnoPar®.

  • Keep your CinnoPar® Delivery Device in the refrigerator between 36°F to 46°F (2°C to 8°C). Do not freeze the CinnoPar® Delivery Device. Do not use CinnoPar® if it has been frozen. Don’t use the medicine after expiration date.
  • Discard CinnoPar®, 30 days after first use even if it has medicine in it.
  • CinnoPar® must be injected. You should inject it once a day in your thighs or abdomen subcutaneously. Before first injection, have your health care provider (physician, nurse or…) teach you the instruction.

You should not take CinnoPar® for more than 2 years over your lifetime.

• The daily dosing of the drug is 20 mcg which is equal to 0.08 cc.

•0.08 cc means 8 units on the Pen. For this purpose, rotate the dose dialer until “8” aligns with the pointer in the dose window to set dose to 8 units.

•Do not transfer the medicine from the CinnoPar® delivery device to a syringe. This can result in taking the wrong dose of CinnoPar®.

•CinnoPar® should look clear and colorless. Do not use CinnoPar® if it has particles in it, or if it is cloudy or colored.

•After each use, safely remove the needle, recap the delivery device, and put it back in the refrigerator right away.

•You can take CinnoPar® with or without food or drink.

Active ingredient: Teriparatide.

Inactive ingredients: glacial acetic acid, sodium acetate (anhydrous), mannitol, metacresol, and water for injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4.


If your CinnoPar® Delivery Device isn't working as it should, please review the leaflet of product.


After puberty, due to the closure of growth plates, the medicine will have little impact on increasing the height. However, CinnaTropin® has some other metabolic effects, and the decision on continuing or stopping the treatment should be based on physician’s opinion.

After the initial injection, each pen can be stored for up to 3 weeks at below the room temperature (<25°C).

The secretion of endogenous growth hormone occurs at night, 2-3 hours after the onset of sleep. It is better to use CinnaTropin® at night and before bed in order to simulate the natural cycle of the hormone.



Tt is advisable that Cinnal-f® reach to the room temperature prior to injection. For this purpose, a maximum of half an hour is sufficient.

If injection site reactions such as pain, redness, inflammation, and etc. occur, it is better to delay bathing until symptoms are resolved. Otherwise, bathing is permitted half an hour after the injection.

Cinnal-f® should be administered subcutaneously at a 90° angle. The best areas for administration of Cinnal-f® are:

  • Front of the thighs (at least 7.5 cm below the hip and above the knees).
  • Belly (below the ribs and above the hip bones, at least 5 cm away from the belly button).

Patients with porphyria or a family history of porphyria should be closely monitored during treatment with Cinnal-f®. Deterioration or a first appearance of this condition may require cessation of treatment.

  • Conventional (Fixed dose): I) Starting a constant daily dose of 75–150 IU of FSH from day 2-3. II) Monitoring USG and E2 levels. III) Continuing FSH until a follicle >18 mm is observed
  • Step-Up Protocol: I) Starting with 75–150 IU of FSH on day 2-3 and continuing that dose for 5–7 days. II) If the follicular and estradiol response are inadequate; the dose is increased by 37.5–75 IU for another 5–7 days. III) If necessary, another 37.5 IU incremental increase can be used until an appropriate response obtained.
  • Step-Down Protocol: I) beginning with 150 IU of FSH on day 2-3 which is continued for 2-3 days. II) The dose is reduced to 75 IU for another 3 days. III) Monitoring USG and E2 levels. If follicles >10 mm are observed on TVS, the dose is decreased in two steps. The last dose is then continued till the day of hCG injection
  • Chronic Low-Dose Step-Up (Low-Slow): I) Starting dose: 37.5–75 units/day of FSH and a stepwise increase in subsequent doses. II) Serum E2 and USG are monitored on day 7. If Serum E2>200 pg/ml or follicle size> 10 mm, the same dose is continued. III) Otherwise, if E2 and follicle size were lower than the above-mentioned cut-offs, the daily dose is increased by an increment of 37.5 units/week, till the serum E2 level rises adequately.
  • Sequential: I) start with 37.5–75 IU/day of FSH which is increased by 50 % or 37.5 IU after 14 days in case of no ovarian response. II) Thereafter, any further FSH increment is made by 37.5–75 IU at weekly intervals to a maximum of 225 IU/day. III) Once dominant follicle emerges and reaches a diameter of 14 mm, the dose is reduced by 50 %

CinnaGen has sponsored four clinical trials with Cinnal-f® so far. In these clinical trials efficacy and safety of Cinnal-f® was compared with the reference product (Gonal-f®). In a randomized, phase III, triple-blind study that was conducted in patients referring to Vali-e-Asr Hospital (A referral infertility hospital, Tehran, Iran) Cinnal-f® proved to be non-inferior to Gonal-f® in terms of efficacy and safety.


No. The evaluation of changes in height and rate of growth should be conducted by the physician.  It is important to compare a person’s growth with his previous history of growth which is usually performed by the assessment of growth curves. In addition to increasing the growth rate, CinnaTropin® is effective in increasing the metabolism of lipids, proteins, carbohydrates, and stimulation of making blood cells. Therefore, taking the medicine should not be stopped or changed against the physician’s advice.